192 related articles for article (PubMed ID: 29096381)
21. Discovery of selective dengue virus inhibitors using combination of molecular fingerprint-based virtual screening protocols, structure-based pharmacophore model development, molecular dynamics simulations and in vitro studies.
Mirza SB; Lee RCH; Chu JJH; Salmas RE; Mavromoustakos T; Durdagi S
J Mol Graph Model; 2018 Jan; 79():88-102. PubMed ID: 29156382
[TBL] [Abstract][Full Text] [Related]
22. Antiviral compounds discovered by virtual screening of small-molecule libraries against dengue virus E protein.
Zhou Z; Khaliq M; Suk JE; Patkar C; Li L; Kuhn RJ; Post CB
ACS Chem Biol; 2008 Dec; 3(12):765-75. PubMed ID: 19053243
[TBL] [Abstract][Full Text] [Related]
23. Discovery of Immunologically Inspired Small Molecules That Target the Viral Envelope Protein.
Lian W; Jang J; Potisopon S; Li PC; Rahmeh A; Wang J; Kwiatkowski NP; Gray NS; Yang PL
ACS Infect Dis; 2018 Sep; 4(9):1395-1406. PubMed ID: 30027735
[TBL] [Abstract][Full Text] [Related]
24. Looking for inhibitors of the dengue virus NS5 RNA-dependent RNA-polymerase using a molecular docking approach.
Galiano V; Garcia-Valtanen P; Micol V; Encinar JA
Drug Des Devel Ther; 2016; 10():3163-3181. PubMed ID: 27784988
[TBL] [Abstract][Full Text] [Related]
25. Receptor-Guided De Novo Design of Dengue Envelope Protein Inhibitors.
Desai VH; Kumar SP; Pandya HA; Solanki HA
Appl Biochem Biotechnol; 2015 Oct; 177(4):861-78. PubMed ID: 26299376
[TBL] [Abstract][Full Text] [Related]
26. Diterpenes/Diterpenoids and Their Derivatives as Potential Bioactive Leads against Dengue Virus: A Computational and Network Pharmacology Study.
Khan RA; Hossain R; Siyadatpanah A; Al-Khafaji K; Khalipha ABR; Dey D; Asha UH; Biswas P; Saikat ASM; Chenari HA; Wilairatana P; Islam MT
Molecules; 2021 Nov; 26(22):. PubMed ID: 34833913
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica.
Roehrig JT; Bolin RA; Kelly RG
Virology; 1998 Jul; 246(2):317-28. PubMed ID: 9657950
[TBL] [Abstract][Full Text] [Related]
28.
Panchal R; Bapat S; Mukherjee S; Chowdhary A
Indian J Pharmacol; 2021; 53(6):471-479. PubMed ID: 34975135
[TBL] [Abstract][Full Text] [Related]
29. In silico design of peptide inhibitors for Dengue virus to treat Dengue virus-associated infections.
Ajmal A; Shahab M; Waqas M; Zheng G; Zulfat M; Bin Jardan YA; Wondmie GF; Bourhia M; Ali I
Sci Rep; 2024 Jun; 14(1):13130. PubMed ID: 38849372
[TBL] [Abstract][Full Text] [Related]
30. A small molecule fusion inhibitor of dengue virus.
Poh MK; Yip A; Zhang S; Priestle JP; Ma NL; Smit JM; Wilschut J; Shi PY; Wenk MR; Schul W
Antiviral Res; 2009 Dec; 84(3):260-6. PubMed ID: 19800368
[TBL] [Abstract][Full Text] [Related]
31. High-content assay to identify inhibitors of dengue virus infection.
Shum D; Smith JL; Hirsch AJ; Bhinder B; Radu C; Stein DA; Nelson JA; Früh K; Djaballah H
Assay Drug Dev Technol; 2010 Oct; 8(5):553-70. PubMed ID: 20973722
[TBL] [Abstract][Full Text] [Related]
32. A small-molecule dengue virus entry inhibitor.
Wang QY; Patel SJ; Vangrevelinghe E; Xu HY; Rao R; Jaber D; Schul W; Gu F; Heudi O; Ma NL; Poh MK; Phong WY; Keller TH; Jacoby E; Vasudevan SG
Antimicrob Agents Chemother; 2009 May; 53(5):1823-31. PubMed ID: 19223625
[TBL] [Abstract][Full Text] [Related]
33. Combinatorial computational approaches to identify tetracycline derivatives as flavivirus inhibitors.
Yang JM; Chen YF; Tu YY; Yen KR; Yang YL
PLoS One; 2007 May; 2(5):e428. PubMed ID: 17502914
[TBL] [Abstract][Full Text] [Related]
34. Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site.
Smith SA; Nivarthi UK; de Alwis R; Kose N; Sapparapu G; Bombardi R; Kahle KM; Pfaff JM; Lieberman S; Doranz BJ; de Silva AM; Crowe JE
J Virol; 2016 Jan; 90(2):780-9. PubMed ID: 26512092
[TBL] [Abstract][Full Text] [Related]
35. Interaction and inhibition of dengue envelope glycoprotein with mammalian receptor DC-sign, an in-silico approach.
Shah M; Wadood A; Rahman Z; Husnain T
PLoS One; 2013; 8(3):e59211. PubMed ID: 23527139
[TBL] [Abstract][Full Text] [Related]
36. Discovery of antiviral molecules for dengue: In silico search and biological evaluation.
Cabarcas-Montalvo M; Maldonado-Rojas W; Montes-Grajales D; Bertel-Sevilla A; Wagner-Döbler I; Sztajer H; Reck M; Flechas-Alarcon M; Ocazionez R; Olivero-Verbel J
Eur J Med Chem; 2016 Mar; 110():87-97. PubMed ID: 26807547
[TBL] [Abstract][Full Text] [Related]
37. 3-O-sulfated glucuronide derivative as a potential anti-dengue virus agent.
Hidari KI; Ikeda K; Watanabe I; Abe T; Sando A; Itoh Y; Tokiwa H; Morita K; Suzuki T
Biochem Biophys Res Commun; 2012 Aug; 424(3):573-8. PubMed ID: 22776202
[TBL] [Abstract][Full Text] [Related]
38. Structure-based screening and validation of potential dengue virus inhibitors through classical and QM/MM affinity estimation.
Ahmed M; Kumar A; Hobman TC; Barakat K
J Mol Graph Model; 2019 Jul; 90():128-143. PubMed ID: 31082639
[TBL] [Abstract][Full Text] [Related]
39. Antiviral activity of chondroitin sulphate E targeting dengue virus envelope protein.
Kato D; Era S; Watanabe I; Arihara M; Sugiura N; Kimata K; Suzuki Y; Morita K; Hidari KI; Suzuki T
Antiviral Res; 2010 Nov; 88(2):236-43. PubMed ID: 20851716
[TBL] [Abstract][Full Text] [Related]
40. Dengue Virus Inhibition Targets: A Review and Docking Study.
Scotti L; Scotti MT; Yarla NS; Monteiro AFM; de Oliveira Viana J; Dantzger DRC; Ishiki HM
Curr Top Med Chem; 2018; 18(18):1522-1530. PubMed ID: 30360718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
